Biotech has a lot of catalysts converging right now. NTHI has an FDA meeting in November for their brain cancer drug NEO212. They just locked in their Phase 2 dose and paid off $6M in preferred shares. The CEO also bought $115k in stock on the open market. CNTB reported Phase 2 data for their COPD drug, showing an 81% drop in treatment failure vs placebo. They are planning to talk to the FDA about starting Phase 3. VBIO finished making an oral version of their radiation drug Entolimod so it doesn't need to be injected. They are waiting on a regulatory decision from Ukraine in Q4. LLY posted Phase 3 data for their new weight loss drug retatrutide. The 12mg dose showed about 21% weight loss over 80 weeks. They plan to file for FDA approval in Q1 2027.